Article
OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care® class of inductees.
OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with relevant, insightful information on patient care, is pleased to announce the Eighth Annual Giants of Cancer Care® class of inductees. The virtual awards ceremony will be held on Nov. 5th at 7.30 pm EST and will be available on-demand at www.giantsofcancercare.com after the conclusion of the event.
“The members of the 2020 class of Giants of Cancer Care® are oncology legends who have made remarkable differences in the cancer care landscape,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, the parent company of OncLive®. “Each inductee has worked tirelessly to advance the field of oncology with their contributions in research and clinical practice, and we look forward to recognizing these respected health care professionals at this year’s Giants of Cancer Care® virtual celebration in November.”
This year’s Giants of Cancer Care® inductees by award category are:
The Giants of Cancer Care® program has celebrated more than 98 oncology legends since 2013 for their groundbreaking achievements in oncology research and clinical practice. Individuals named Giants of Cancer Care® have reached landmark successes within the global field of oncology and their work has significantly impacted patient care and research. Out of 818 nominations, only 15 oncologists were selected to the prestigious 2020 class of Giants of Cancer Care®.
The Giants of Cancer Care® Steering Committee selects semifinalists from nominations submitted each year and the Selection Committee—comprised of more than 120 eminent oncologists, clinicians and researchers—then votes on the finalists in each category.
For more information and to register to attend the virtual awards ceremony, click here.
Supporters of the 2020 program include Athenex, Incyte, and Pfizer.